

ASX Announcement 13 January 2021

Carl Zeiss Meditec AG Product Orders

Highlights:

- Receipt of orders from Carl Zeiss Meditec AG (CZM) for approx. A\$350k
- Continued diversification of OptiScan Revenue Streams with receipts of A\$570k from the balance
 of the payments for the 2 FIVE2 (ViewnVivo) sales to China based customers, the BioMedTech
 Horizons Program grant and from CZM in the December 2020 quarter.

Carl Zeiss Meditec AG Orders

OptiScan Imaging Limited (ASX: OIL) ('the Company' or 'OptiScan') is pleased to advise that it has received orders from Carl Zeiss Meditec AG pursuant to its Co-operation Agreement for approximately A\$350k.

OptiScan's CEO and Executive Chairman Darren Lurie, said:

"The orders from CZM represent the continuation of CZM's commercial rollout of the CONVIVO® developed as part of the co-operation agreement between CZM and OptiScan.

We are also very pleased that OptiScan continues to diversify its revenue streams and cash flows. Receipts in the December 2020 quarter included \$570k from the final payments for the 2 (two) FIVE2 (ViewnVivo) systems sold to China based customers, the BioMedTech Horizons Program grant to support the University of Melbourne's Melbourne Dental School trial and payments from CZM."

For and on behalf of the Board:

Darren Lurie CEO and Executive Chairman – Optiscan Imaging Limited E: dlurie@optiscan.com

This announcement has been authorised for release by the Board of OIL.

About Optiscan

Optiscan is a global leader in the development of microscopic imaging and related technologies for screening, surgery and medical research. Based in Melbourne, Australia, Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant "virtual biopsies" with applications for cancer screening and surgical margin determination. Optiscan's technology has the capability to improve patient welfare, reduce hospital costs, improve accuracy and reduce the need for multiple procedures. The technology is approved for use in brain surgery and is involved in a number of oral cancer and breast cancer studies.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333 **Website** www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia